25 XP   0   0   10

Sk Biopharmaceuticals Co Ltd
Buy, Hold or Sell?

Let's analyse Sk Biopharmaceuticals Co Ltd together

PenkeI guess you are interested in Sk Biopharmaceuticals Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sk Biopharmaceuticals Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sk Biopharmaceuticals Co Ltd

I send you an email if I find something interesting about Sk Biopharmaceuticals Co Ltd.

Quick analysis of Sk Biopharmaceuticals Co Ltd (30 sec.)










What can you expect buying and holding a share of Sk Biopharmaceuticals Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩4,098.30
Expected worth in 1 year
₩4,154.37
How sure are you?
29.4%

+ What do you gain per year?

Total Gains per Share
₩56.07
Return On Investment
0.1%

For what price can you sell your share?

Current Price per Share
₩83,300.00
Expected price per share
₩72,800 - ₩97,900
How sure are you?
50%

1. Valuation of Sk Biopharmaceuticals Co Ltd (5 min.)




Live pricePrice per Share (EOD)

₩83,300.00

Intrinsic Value Per Share

₩-13,910.69 - ₩-16,083.17

Total Value Per Share

₩-9,812.39 - ₩-11,984.87

2. Growth of Sk Biopharmaceuticals Co Ltd (5 min.)




Is Sk Biopharmaceuticals Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$224.6m$260.1m-$41.1m-18.8%

How much money is Sk Biopharmaceuticals Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$5.7m-$24.4m$18.6m324.0%
Net Profit Margin-11.1%-64.3%--

How much money comes from the company's main activities?

3. Financial Health of Sk Biopharmaceuticals Co Ltd (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#232 / 1010

Most Revenue
#136 / 1010

Most Profit
#458 / 1010

Most Efficient
#466 / 1010

What can you expect buying and holding a share of Sk Biopharmaceuticals Co Ltd? (5 min.)

Welcome investor! Sk Biopharmaceuticals Co Ltd's management wants to use your money to grow the business. In return you get a share of Sk Biopharmaceuticals Co Ltd.

What can you expect buying and holding a share of Sk Biopharmaceuticals Co Ltd?

First you should know what it really means to hold a share of Sk Biopharmaceuticals Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Sk Biopharmaceuticals Co Ltd is ₩83,300. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Sk Biopharmaceuticals Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sk Biopharmaceuticals Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩4,098.30. Based on the TTM, the Book Value Change Per Share is ₩14.02 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-407.42 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Sk Biopharmaceuticals Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.060.0%-0.070.0%-0.310.0%-0.210.0%-0.210.0%
Usd Book Value Change Per Share-0.010.0%0.010.0%-0.290.0%0.170.0%0.170.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.010.0%0.010.0%-0.290.0%0.170.0%0.170.0%
Usd Price Per Share70.28-57.89-51.40-56.63-56.63-
Price to Earnings Ratio290.79--105.35--47.22--43.58--43.58-
Price-to-Total Gains Ratio-5,107.58--5,276.33-73.19--1,540.86--1,540.86-
Price to Book Ratio24.50-20.71-15.54-16.63-16.63-
Price-to-Total Gains Ratio-5,107.58--5,276.33-73.19--1,540.86--1,540.86-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share58.31
Number of shares17
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.17
Usd Total Gains Per Share0.010.17
Gains per Quarter (17 shares)0.172.87
Gains per Year (17 shares)0.6711.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101-90111
201-802312
302-703423
403-604634
503-505745
604-406956
705-308067
805-209278
906-1010389
100700115100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%3.09.00.025.0%3.014.00.017.6%3.014.00.017.6%3.014.00.017.6%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%5.012.00.029.4%5.012.00.029.4%5.012.00.029.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.017.00.0%0.00.017.00.0%0.00.017.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%5.012.00.029.4%5.012.00.029.4%5.012.00.029.4%

Fundamentals of Sk Biopharmaceuticals Co Ltd

About Sk Biopharmaceuticals Co Ltd

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It also develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL27969 for treatment of advanced solid tumors; SKL13865 clinical trials to treat attention deficit/hyperactivity disorder; and SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder. The company was founded in 1993 and is headquartered in Seongnam-si, South Korea. SK Biopharmaceuticals Co., Ltd. is a subsidiary of SK Inc.

Fundamental data was last updated by Penke on 2024-04-16 19:21:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sk Biopharmaceuticals Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Sk Biopharmaceuticals Co Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Sk Biopharmaceuticals Co Ltd to the Biotechnology industry mean.
  • A Net Profit Margin of 5.3% means that ₩0.05 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 5.3%. The company is making a profit. +1
  • The TTM is -11.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ5.3%TTM-11.1%+16.4%
TTM-11.1%YOY-64.3%+53.2%
TTM-11.1%5Y-1,991.9%+1,980.8%
5Y-1,991.9%10Y-1,991.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3%-207.2%+212.5%
TTM-11.1%-216.8%+205.7%
YOY-64.3%-282.3%+218.0%
5Y-1,991.9%-436.8%-1,555.1%
10Y-1,991.9%-597.3%-1,394.6%
1.1.2. Return on Assets

Shows how efficient Sk Biopharmaceuticals Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Sk Biopharmaceuticals Co Ltd to the Biotechnology industry mean.
  • 0.9% Return on Assets means that Sk Biopharmaceuticals Co Ltd generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 0.9%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -1.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.9%TTM-1.2%+2.2%
TTM-1.2%YOY-5.4%+4.2%
TTM-1.2%5Y-7.2%+6.0%
5Y-7.2%10Y-7.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9%-13.3%+14.2%
TTM-1.2%-12.8%+11.6%
YOY-5.4%-11.6%+6.2%
5Y-7.2%-13.8%+6.6%
10Y-7.2%-15.6%+8.4%
1.1.3. Return on Equity

Shows how efficient Sk Biopharmaceuticals Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Sk Biopharmaceuticals Co Ltd to the Biotechnology industry mean.
  • 2.4% Return on Equity means Sk Biopharmaceuticals Co Ltd generated ₩0.02 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 2.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -2.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ2.4%TTM-2.8%+5.2%
TTM-2.8%YOY-9.6%+6.8%
TTM-2.8%5Y-4.8%+2.0%
5Y-4.8%10Y-4.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4%-16.9%+19.3%
TTM-2.8%-16.1%+13.3%
YOY-9.6%-14.9%+5.3%
5Y-4.8%-19.3%+14.5%
10Y-4.8%-20.1%+15.3%

1.2. Operating Efficiency of Sk Biopharmaceuticals Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Sk Biopharmaceuticals Co Ltd is operating .

  • Measures how much profit Sk Biopharmaceuticals Co Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Sk Biopharmaceuticals Co Ltd to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-15.5%+15.5%
TTM-15.5%YOY-61.7%+46.2%
TTM-15.5%5Y-2,284.1%+2,268.6%
5Y-2,284.1%10Y-2,284.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM-15.5%-238.5%+223.0%
YOY-61.7%-288.4%+226.7%
5Y-2,284.1%-486.2%-1,797.9%
10Y-2,284.1%-628.4%-1,655.7%
1.2.2. Operating Ratio

Measures how efficient Sk Biopharmaceuticals Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.99 means that the operating costs are ₩0.99 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 0.994. The company is less efficient in keeping operating costs low.
  • The TTM is 0.967. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.994TTM0.967+0.027
TTM0.967YOY0.692+0.275
TTM0.9675Y24.414-23.447
5Y24.41410Y24.4140.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9943.235-2.241
TTM0.9673.310-2.343
YOY0.6923.838-3.146
5Y24.4145.679+18.735
10Y24.4147.823+16.591

1.3. Liquidity of Sk Biopharmaceuticals Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Sk Biopharmaceuticals Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.02 means the company has ₩2.02 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 2.023. The company is able to pay all its short-term debts. +1
  • The TTM is 2.168. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.023TTM2.168-0.146
TTM2.168YOY3.214-1.046
TTM2.1685Y3.497-1.328
5Y3.49710Y3.4970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0233.863-1.840
TTM2.1684.169-2.001
YOY3.2145.337-2.123
5Y3.4976.122-2.625
10Y3.4976.434-2.937
1.3.2. Quick Ratio

Measures if Sk Biopharmaceuticals Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Sk Biopharmaceuticals Co Ltd to the Biotechnology industry mean.
  • A Quick Ratio of 0.47 means the company can pay off ₩0.47 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 0.465. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.759. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.465TTM0.759-0.294
TTM0.759YOY1.684-0.925
TTM0.7595Y1.749-0.990
5Y1.74910Y1.7490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4653.504-3.039
TTM0.7593.991-3.232
YOY1.6845.371-3.687
5Y1.7496.088-4.339
10Y1.7496.395-4.646

1.4. Solvency of Sk Biopharmaceuticals Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Sk Biopharmaceuticals Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Sk Biopharmaceuticals Co Ltd to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.56 means that Sk Biopharmaceuticals Co Ltd assets are financed with 55.6% credit (debt) and the remaining percentage (100% - 55.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 0.556. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.546. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.556TTM0.546+0.011
TTM0.546YOY0.430+0.116
TTM0.5465Y0.480+0.065
5Y0.48010Y0.4800.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5560.339+0.217
TTM0.5460.337+0.209
YOY0.4300.271+0.159
5Y0.4800.368+0.112
10Y0.4800.388+0.092
1.4.2. Debt to Equity Ratio

Measures if Sk Biopharmaceuticals Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Sk Biopharmaceuticals Co Ltd to the Biotechnology industry mean.
  • A Debt to Equity ratio of 141.8% means that company has ₩1.42 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sk Biopharmaceuticals Co Ltd:

  • The MRQ is 1.418. The company is able to pay all its debts with equity. +1
  • The TTM is 1.289. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.418TTM1.289+0.129
TTM1.289YOY0.783+0.506
TTM1.2895Y0.629+0.660
5Y0.62910Y0.6290.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4180.392+1.026
TTM1.2890.403+0.886
YOY0.7830.335+0.448
5Y0.6290.427+0.202
10Y0.6290.461+0.168

2. Market Valuation of Sk Biopharmaceuticals Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Sk Biopharmaceuticals Co Ltd generates.

  • Above 15 is considered overpriced but always compare Sk Biopharmaceuticals Co Ltd to the Biotechnology industry mean.
  • A PE ratio of 290.79 means the investor is paying ₩290.79 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sk Biopharmaceuticals Co Ltd:

  • The EOD is 241.261. Based on the earnings, the company is expensive. -2
  • The MRQ is 290.788. Based on the earnings, the company is expensive. -2
  • The TTM is -105.350. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD241.261MRQ290.788-49.527
MRQ290.788TTM-105.350+396.138
TTM-105.350YOY-47.219-58.132
TTM-105.3505Y-43.578-61.773
5Y-43.57810Y-43.5780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD241.261-2.300+243.561
MRQ290.788-2.656+293.444
TTM-105.350-2.718-102.632
YOY-47.219-4.145-43.074
5Y-43.578-6.258-37.320
10Y-43.578-6.315-37.263
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sk Biopharmaceuticals Co Ltd:

  • The EOD is -84.916. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -102.348. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -136.702. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-84.916MRQ-102.348+17.432
MRQ-102.348TTM-136.702+34.355
TTM-136.702YOY-35.594-101.108
TTM-136.7025Y-61.676-75.027
5Y-61.67610Y-61.6760.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-84.916-2.974-81.942
MRQ-102.348-3.306-99.042
TTM-136.702-3.508-133.194
YOY-35.594-5.613-29.981
5Y-61.676-8.378-53.298
10Y-61.676-8.873-52.803
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Sk Biopharmaceuticals Co Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 24.50 means the investor is paying ₩24.50 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Sk Biopharmaceuticals Co Ltd:

  • The EOD is 20.326. Based on the equity, the company is expensive. -2
  • The MRQ is 24.498. Based on the equity, the company is expensive. -2
  • The TTM is 20.706. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD20.326MRQ24.498-4.172
MRQ24.498TTM20.706+3.792
TTM20.706YOY15.543+5.163
TTM20.7065Y16.626+4.080
5Y16.62610Y16.6260.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.3261.914+18.412
MRQ24.4982.116+22.382
TTM20.7062.097+18.609
YOY15.5432.881+12.662
5Y16.6263.550+13.076
10Y16.6263.936+12.690
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Sk Biopharmaceuticals Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---19.65714.017-240%-407.425+1973%241.076-108%241.076-108%
Book Value Per Share--4098.3003994.927+3%4745.899-14%4307.775-5%4307.775-5%
Current Ratio--2.0232.168-7%3.214-37%3.497-42%3.497-42%
Debt To Asset Ratio--0.5560.546+2%0.430+29%0.480+16%0.480+16%
Debt To Equity Ratio--1.4181.289+10%0.783+81%0.629+126%0.629+126%
Dividend Per Share----0%-0%-0%-0%
Eps--86.317-104.972+222%-445.106+616%-296.448+443%-296.448+443%
Free Cash Flow Per Share---245.242-311.092+27%-529.543+116%-485.065+98%-485.065+98%
Free Cash Flow To Equity Per Share---245.242-319.809+30%-98.855-60%-94.059-62%-94.059-62%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---16083.169--------
Intrinsic Value_10Y_min---13910.694--------
Intrinsic Value_1Y_max---1553.945--------
Intrinsic Value_1Y_min---1526.317--------
Intrinsic Value_3Y_max---4712.952--------
Intrinsic Value_3Y_min---4498.485--------
Intrinsic Value_5Y_max---7925.010--------
Intrinsic Value_5Y_min---7352.004--------
Market Cap6523489560000.000-21%7862650300000.0006476505775000.000+21%5750150381250.000+37%6335081258823.529+24%6335081258823.529+24%
Net Profit Margin--0.053-0.111+308%-0.643+1306%-19.919+37451%-19.919+37451%
Operating Margin----0.1550%-0.6170%-22.8410%-22.8410%
Operating Ratio--0.9940.967+3%0.692+44%24.414-96%24.414-96%
Pb Ratio20.326-21%24.49820.706+18%15.543+58%16.626+47%16.626+47%
Pe Ratio241.261-21%290.788-105.350+136%-47.219+116%-43.578+115%-43.578+115%
Price Per Share83300.000-21%100400.00082700.000+21%73425.000+37%80894.118+24%80894.118+24%
Price To Free Cash Flow Ratio-84.916+17%-102.348-136.702+34%-35.594-65%-61.676-40%-61.676-40%
Price To Total Gains Ratio-4237.668+17%-5107.585-5276.333+3%73.191-7078%-1540.857-70%-1540.857-70%
Quick Ratio--0.4650.759-39%1.684-72%1.749-73%1.749-73%
Return On Assets--0.009-0.012+233%-0.054+683%-0.072+875%-0.072+875%
Return On Equity--0.024-0.028+218%-0.096+503%-0.048+301%-0.048+301%
Total Gains Per Share---19.65714.017-240%-407.425+1973%241.076-108%241.076-108%
Usd Book Value--224665836.192218998979.294+3%260166716.152-14%237422037.896-5%237422037.896-5%
Usd Book Value Change Per Share---0.0140.010-240%-0.285+1973%0.169-108%0.169-108%
Usd Book Value Per Share--2.8692.796+3%3.322-14%3.015-5%3.015-5%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.060-0.073+222%-0.312+616%-0.208+443%-0.208+443%
Usd Free Cash Flow---13444006.695-17053857.464+27%-29029176.696+116%-27252005.503+103%-27252005.503+103%
Usd Free Cash Flow Per Share---0.172-0.218+27%-0.371+116%-0.340+98%-0.340+98%
Usd Free Cash Flow To Equity Per Share---0.172-0.224+30%-0.069-60%-0.066-62%-0.066-62%
Usd Market Cap4566442692.000-21%5503855210.0004533554042.500+21%4025105266.875+37%4434556881.176+24%4434556881.176+24%
Usd Price Per Share58.310-21%70.28057.890+21%51.398+37%56.626+24%56.626+24%
Usd Profit--4731852.202-5754498.647+222%-24400403.650+616%-16797926.987+455%-16797926.987+455%
Usd Revenue--88729093.31362106022.263+43%43081346.082+106%43067018.478+106%43067018.478+106%
Usd Total Gains Per Share---0.0140.010-240%-0.285+1973%0.169-108%0.169-108%
 EOD+4 -4MRQTTM+19 -13YOY+18 -145Y+15 -1710Y+15 -17

3.2. Fundamental Score

Let's check the fundamental score of Sk Biopharmaceuticals Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15241.261
Price to Book Ratio (EOD)Between0-120.326
Net Profit Margin (MRQ)Greater than00.053
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.465
Current Ratio (MRQ)Greater than12.023
Debt to Asset Ratio (MRQ)Less than10.556
Debt to Equity Ratio (MRQ)Less than11.418
Return on Equity (MRQ)Greater than0.150.024
Return on Assets (MRQ)Greater than0.050.009
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Sk Biopharmaceuticals Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.411
Ma 20Greater thanMa 5086,690.000
Ma 50Greater thanMa 10090,116.000
Ma 100Greater thanMa 20091,035.000
OpenGreater thanClose84,100.000
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Long-term Assets Other  3,211,192-3,211,191001-10-10
Income before Tax  -46,549,15344,055,104-2,494,049-22,558,396-25,052,4455,227,563-19,824,88223,338,4963,513,614
Net Income  -43,859,41641,490,690-2,368,726-20,973,621-23,342,3479,410,782-13,931,56520,691,3546,759,789
Net Income from Continuing Operations  -43,859,41641,490,690-2,368,726-20,973,621-23,342,3474,928,262-18,414,08527,159,7548,745,669



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets723,170,577
Total Liabilities402,219,383
Total Stockholder Equity283,686,371
 As reported
Total Liabilities 402,219,383
Total Stockholder Equity+ 283,686,371
Total Assets = 723,170,577

Assets

Total Assets723,170,577
Total Current Assets488,722,241
Long-term Assets234,448,336
Total Current Assets
Cash And Cash Equivalents 239,700,042
Short-term Investments 1,418,394
Net Receivables 111,000,939
Inventory 102,525,491
Other Current Assets 647,245
Total Current Assets  (as reported)488,722,241
Total Current Assets  (calculated)455,292,112
+/- 33,430,130
Long-term Assets
Property Plant Equipment 47,753,145
Goodwill 3,391,911
Intangible Assets 23,632,696
Long-term Assets  (as reported)234,448,336
Long-term Assets  (calculated)74,777,752
+/- 159,670,584

Liabilities & Shareholders' Equity

Total Current Liabilities241,618,589
Long-term Liabilities160,600,794
Total Stockholder Equity283,686,371
Total Current Liabilities
Short Long Term Debt 50,000,000
Accounts payable 2,345,801
Other Current Liabilities 127,105
Total Current Liabilities  (as reported)241,618,589
Total Current Liabilities  (calculated)52,472,905
+/- 189,145,683
Long-term Liabilities
Long term Debt 94,484,300
Capital Lease Obligations Min Short Term Debt33,565,751
Long-term Liabilities Other 22,235,873
Long-term Liabilities  (as reported)160,600,794
Long-term Liabilities  (calculated)150,285,924
+/- 10,314,870
Total Stockholder Equity
Total Stockholder Equity (as reported)283,686,371
Total Stockholder Equity (calculated)0
+/- 283,686,371
Other
Capital Stock39,156,625
Common Stock Shares Outstanding 78,313
Net Invested Capital 428,170,671
Net Working Capital 247,103,653
Property Plant and Equipment Gross 102,351,845



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-03-31
> Total Assets 
0
139,073,135
187,925,685
765,507,675
560,762,090
500,241,425
623,581,123
575,028,469
523,357,215
643,652,339
620,638,495
609,022,673
729,834,061
664,241,139
656,029,436
631,160,097
751,052,302
723,170,577
723,170,577751,052,302631,160,097656,029,436664,241,139729,834,061609,022,673620,638,495643,652,339523,357,215575,028,469623,581,123500,241,425560,762,090765,507,675187,925,685139,073,1350
   > Total Current Assets 
0
98,680,712
143,269,947
716,217,476
500,775,923
434,602,624
552,926,747
505,275,208
452,062,246
471,219,268
444,078,678
418,521,135
523,398,307
487,924,713
456,145,202
435,465,950
501,050,572
488,722,241
488,722,241501,050,572435,465,950456,145,202487,924,713523,398,307418,521,135444,078,678471,219,268452,062,246505,275,208552,926,747434,602,624500,775,923716,217,476143,269,94798,680,7120
       Cash And Cash Equivalents 
0
51,140,948
111,118,690
575,978,937
145,928,530
59,333,239
184,615,115
127,039,458
253,184,740
225,922,278
171,179,192
112,852,142
115,445,837
104,059,703
103,577,077
106,443,048
271,392,409
239,700,042
239,700,042271,392,409106,443,048103,577,077104,059,703115,445,837112,852,142171,179,192225,922,278253,184,740127,039,458184,615,11559,333,239145,928,530575,978,937111,118,69051,140,9480
       Short-term Investments 
0
31,233,514
8,680,460
108,524,970
318,331,850
328,657,262
168,047,850
168,023,000
108,412,790
108,417,050
153,439,880
173,744,690
251,578,280
201,394,030
151,434,235
116,444,135
1,479,337
1,418,394
1,418,3941,479,337116,444,135151,434,235201,394,030251,578,280173,744,690153,439,880108,417,050108,412,790168,023,000168,047,850328,657,262318,331,850108,524,9708,680,46031,233,5140
       Net Receivables 
0
2,138,236
391,176
4,126,353
7,027,618
12,552,781
154,646,596
149,283,589
23,849,530
57,360,477
39,584,618
47,376,568
59,581,512
66,450,536
68,726,031
82,393,677
92,468,895
111,000,939
111,000,93992,468,89582,393,67768,726,03166,450,53659,581,51247,376,56839,584,61857,360,47723,849,530149,283,589154,646,59612,552,7817,027,6184,126,353391,1762,138,2360
       Other Current Assets 
0
2,210,059
223,935
2,949,175
619,128
99,948
1,725,070
2,110,339
5,605,819
6,621,576
6,695,213
2,468,650
2,806,248
6,366,359
1,271,429
2,276,357
636,357
647,245
647,245636,3572,276,3571,271,4296,366,3592,806,2482,468,6506,695,2136,621,5765,605,8192,110,3391,725,07099,948619,1282,949,175223,9352,210,0590
   > Long-term Assets 
0
40,392,423
44,655,738
49,290,200
59,986,168
65,638,801
70,654,376
69,753,261
71,294,969
172,433,072
176,559,817
190,501,538
206,435,755
176,316,427
199,884,234
195,694,147
250,001,730
234,448,336
234,448,336250,001,730195,694,147199,884,234176,316,427206,435,755190,501,538176,559,817172,433,07271,294,96969,753,26170,654,37665,638,80159,986,16849,290,20044,655,73840,392,4230
       Property Plant Equipment 
0
25,896,761
26,609,763
15,460,894
25,058,299
24,233,209
25,402,147
23,866,732
23,157,728
22,937,541
20,861,607
20,816,891
20,796,311
20,349,740
18,388,468
16,489,720
50,027,932
47,753,145
47,753,14550,027,93216,489,72018,388,46820,349,74020,796,31120,816,89120,861,60722,937,54123,157,72823,866,73225,402,14724,233,20925,058,29915,460,89426,609,76325,896,7610
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,215,426
3,391,911
3,391,9114,215,4260000000000000000
       Intangible Assets 
0
883,318
2,389,695
18,902,830
18,456,910
19,695,121
19,635,374
18,935,031
18,568,566
18,899,654
18,759,309
18,714,710
18,727,590
17,180,831
17,304,071
16,723,915
28,233,334
23,632,696
23,632,69628,233,33416,723,91517,304,07117,180,83118,727,59018,714,71018,759,30918,899,65418,568,56618,935,03119,635,37419,695,12118,456,91018,902,8302,389,695883,3180
       Other Assets 
0
13,605,343
15,649,280
14,919,476
16,463,958
14,861,749
15,833,641
17,168,284
18,683,957
22,931,290
27,326,907
31,007,383
36,862,441
38,827,215
0
43,665,525
0
0
0043,665,525038,827,21536,862,44131,007,38327,326,90722,931,29018,683,95717,168,28415,833,64114,861,74916,463,95814,919,47615,649,28013,605,3430
> Total Liabilities 
0
152,098,398
265,138,386
257,923,927
118,031,327
121,174,852
115,603,804
134,557,844
127,261,638
199,464,893
209,378,649
232,527,524
347,482,567
347,680,679
339,779,602
339,428,988
428,561,701
402,219,383
402,219,383428,561,701339,428,988339,779,602347,680,679347,482,567232,527,524209,378,649199,464,893127,261,638134,557,844115,603,804121,174,852118,031,327257,923,927265,138,386152,098,3980
   > Total Current Liabilities 
0
145,640,745
256,057,470
249,232,179
98,428,466
70,595,492
66,308,761
89,305,415
83,938,476
148,305,638
122,623,119
143,031,020
157,766,635
163,072,636
186,225,186
195,124,917
254,419,128
241,618,589
241,618,589254,419,128195,124,917186,225,186163,072,636157,766,635143,031,020122,623,119148,305,63883,938,47689,305,41566,308,76170,595,49298,428,466249,232,179256,057,470145,640,7450
       Short Long Term Debt 
0
100,000,000
200,000,000
200,000,000
50,000,000
0
0
0
0
0
0
0
0
0
25,000,000
25,000,000
50,000,000
50,000,000
50,000,00050,000,00025,000,00025,000,00000000000050,000,000200,000,000200,000,000100,000,0000
       Accounts payable 
0
0
7,735,820
4,406,811
475,756
8,953,613
8,679,038
15,190,536
1,261,730
16,931,411
2,354,507
15,113,670
12,042,050
23,106,328
13,998,008
10,602,353
2,736,348
2,345,801
2,345,8012,736,34810,602,35313,998,00823,106,32812,042,05015,113,6702,354,50716,931,4111,261,73015,190,5368,679,0388,953,613475,7564,406,8117,735,82000
       Other Current Liabilities 
0
7,341,329
0
5,556,915
6,673,402
20,192,958
24,554,097
36,644,768
46,729,392
61,117,154
70,774,267
79,472,386
85,252,702
79,287,222
70,896
95,751,671
112,072
127,105
127,105112,07295,751,67170,89679,287,22285,252,70279,472,38670,774,26761,117,15446,729,39236,644,76824,554,09720,192,9586,673,4025,556,91507,341,3290
   > Long-term Liabilities 
0
6,457,653
9,080,916
8,691,748
19,602,861
50,579,361
49,295,043
45,252,429
43,323,162
51,159,255
86,755,530
89,496,503
189,715,932
184,608,043
153,554,416
144,304,071
174,142,573
160,600,794
160,600,794174,142,573144,304,071153,554,416184,608,043189,715,93289,496,50386,755,53051,159,25543,323,16245,252,42949,295,04350,579,36119,602,8618,691,7489,080,9166,457,6530
       Other Liabilities 
0
599,297
1,473,355
1,839,552
4,105,967
37,007,261
35,483,480
32,619,157
31,806,114
40,903,181
35,729,590
36,062,929
32,327,686
34,356,048
0
19,123,778
0
0
0019,123,778034,356,04832,327,68636,062,92935,729,59040,903,18131,806,11432,619,15735,483,48037,007,2614,105,9671,839,5521,473,355599,2970
> Total Stockholder Equity
0
-13,025,262
-77,212,701
507,583,748
442,730,763
379,066,573
507,977,320
440,470,625
396,095,576
444,187,446
411,259,846
376,495,149
382,351,495
316,560,460
316,249,834
291,731,109
285,610,260
283,686,371
283,686,371285,610,260291,731,109316,249,834316,560,460382,351,495376,495,149411,259,846444,187,446396,095,576440,470,625507,977,320379,066,573442,730,763507,583,748-77,212,701-13,025,2620
   Common Stock
0
32,500,000
32,500,000
39,156,625
39,156,625
39,156,625
39,156,625
39,156,625
39,156,625
39,156,625
39,156,625
39,156,625
39,156,625
39,156,625
0
39,156,625
0
0
0039,156,625039,156,62539,156,62539,156,62539,156,62539,156,62539,156,62539,156,62539,156,62539,156,62539,156,62539,156,62532,500,00032,500,0000
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
0
7,382,811
10,394,350
9,290,809
7,712,466
2,013,442
3,138,513
8,716,781
8,575,446
9,324,503
12,697,605
23,270,959
43,991,295
20,111,639
0
21,245,271
0
0
0021,245,271020,111,63943,991,29523,270,95912,697,6059,324,5038,575,4468,716,7813,138,5132,013,4427,712,4669,290,80910,394,3507,382,8110



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue354,891,556
Cost of Revenue-34,082,497
Gross Profit320,809,058320,809,058
 
Operating Income (+$)
Gross Profit320,809,058
Operating Expense-392,413,752
Operating Income-37,522,197-71,604,694
 
Operating Expense (+$)
Research Development137,126,137
Selling General Administrative101,868,434
Selling And Marketing Expenses0
Operating Expense392,413,752238,994,571
 
Net Interest Income (+$)
Interest Income9,317,460
Interest Expense-8,279,609
Other Finance Cost-0
Net Interest Income1,037,851
 
Pretax Income (+$)
Operating Income-37,522,197
Net Interest Income1,037,851
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-43,857,763-37,522,197
EBIT - interestExpense = -8,279,609
-32,882,849
-24,603,240
Interest Expense8,279,609
Earnings Before Interest and Taxes (EBIT)0-35,578,154
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-43,857,763
Tax Provision--8,478,274
Net Income From Continuing Ops-35,379,488-35,379,489
Net Income-32,882,849
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-1,037,851
 

Technical Analysis of Sk Biopharmaceuticals Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sk Biopharmaceuticals Co Ltd. The general trend of Sk Biopharmaceuticals Co Ltd is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sk Biopharmaceuticals Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Sk Biopharmaceuticals Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 90,000 < 90,000 < 97,900.

The bearish price targets are: 80,700 > 73,500 > 72,800.

Tweet this
Sk Biopharmaceuticals Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sk Biopharmaceuticals Co Ltd. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Sk Biopharmaceuticals Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sk Biopharmaceuticals Co Ltd. The current macd is -2,278.05217212.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sk Biopharmaceuticals Co Ltd price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sk Biopharmaceuticals Co Ltd. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sk Biopharmaceuticals Co Ltd price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Sk Biopharmaceuticals Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartSk Biopharmaceuticals Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Sk Biopharmaceuticals Co Ltd. The current adx is 18.16.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Sk Biopharmaceuticals Co Ltd shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Sk Biopharmaceuticals Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sk Biopharmaceuticals Co Ltd. The current sar is 80,914.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Sk Biopharmaceuticals Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sk Biopharmaceuticals Co Ltd. The current rsi is 39.41. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Sk Biopharmaceuticals Co Ltd Daily Relative Strength Index (RSI) ChartSk Biopharmaceuticals Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sk Biopharmaceuticals Co Ltd. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Sk Biopharmaceuticals Co Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Sk Biopharmaceuticals Co Ltd Daily Stochastic Oscillator ChartSk Biopharmaceuticals Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sk Biopharmaceuticals Co Ltd. The current cci is -67.67458603.

Sk Biopharmaceuticals Co Ltd Daily Commodity Channel Index (CCI) ChartSk Biopharmaceuticals Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sk Biopharmaceuticals Co Ltd. The current cmo is -21.87050759.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Sk Biopharmaceuticals Co Ltd Daily Chande Momentum Oscillator (CMO) ChartSk Biopharmaceuticals Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Sk Biopharmaceuticals Co Ltd. The current willr is -71.11111111.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Sk Biopharmaceuticals Co Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Sk Biopharmaceuticals Co Ltd Daily Williams %R ChartSk Biopharmaceuticals Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Sk Biopharmaceuticals Co Ltd.

Sk Biopharmaceuticals Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sk Biopharmaceuticals Co Ltd. The current atr is 2,640.

Sk Biopharmaceuticals Co Ltd Daily Average True Range (ATR) ChartSk Biopharmaceuticals Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sk Biopharmaceuticals Co Ltd. The current obv is 4,908,866.

Sk Biopharmaceuticals Co Ltd Daily On-Balance Volume (OBV) ChartSk Biopharmaceuticals Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sk Biopharmaceuticals Co Ltd. The current mfi is 28.42.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Sk Biopharmaceuticals Co Ltd Daily Money Flow Index (MFI) ChartSk Biopharmaceuticals Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Sk Biopharmaceuticals Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-26WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Sk Biopharmaceuticals Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Sk Biopharmaceuticals Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.411
Ma 20Greater thanMa 5086,690.000
Ma 50Greater thanMa 10090,116.000
Ma 100Greater thanMa 20091,035.000
OpenGreater thanClose84,100.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Sk Biopharmaceuticals Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Sk Biopharmaceuticals Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Sk Biopharmaceuticals Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Sk Biopharmaceuticals Co Ltd

I send you an email if I find something interesting about Sk Biopharmaceuticals Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Sk Biopharmaceuticals Co Ltd.

Receive notifications about Sk Biopharmaceuticals Co Ltd in your mailbox!